Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
McKesson
Express Scripts
Moodys
Harvard Business School

Last Updated: December 2, 2021

DrugPatentWatch Database Preview

Patent: 10,172,808

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 10,172,808
Title:Combinations of mRNAs encoding immune modulating polypeptides and uses thereof
Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36.gamma. (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
Inventor(s): Frederick; Joshua (Boston, MA), Bai; Ailin (Newton, MA), Presnyak; Vladimir (Cambridge, MA), Hoge; Stephen (Brookline, MA), Benenato; Kerry (Sudbury, MA), McFadyen; Iain (Arlington, MA), Kumarasinghe; Ellalahewage Sathyajith (Harvard, MA), Hewitt; Susannah (Jamaica Plain, MA)
Assignee: ModernaTX, Inc. (Cambridge, MA)
Application Number:15/995,889
Patent Claims:see list of patent claims

Details for Patent 10,172,808

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bristol-myers Squibb Company YERVOY ipilimumab Injection 125377 2011-03-25 ⤷  Free Forever Trial 2036-05-18
Merck Sharp & Dohme Corp. KEYTRUDA pembrolizumab For Injection 125514 2014-09-04 ⤷  Free Forever Trial 2036-05-18
Merck Sharp & Dohme Corp. KEYTRUDA pembrolizumab Injection 125514 2015-01-15 ⤷  Free Forever Trial 2036-05-18
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 2014-12-22 ⤷  Free Forever Trial 2036-05-18
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 2017-10-04 ⤷  Free Forever Trial 2036-05-18
Genentech, Inc. TECENTRIQ atezolizumab Injection 761034 2016-05-18 ⤷  Free Forever Trial 2036-05-18
Genentech, Inc. TECENTRIQ atezolizumab Injection 761034 2019-03-08 ⤷  Free Forever Trial 2036-05-18
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
AstraZeneca
Johnson and Johnson
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.